2011
The effects of wedelolactone on cancer cells depend on its redox state
BENEŠ, Petr; Petra ALEXOVA; Lucia KNOPFOVÁ a Jan ŠMARDAZákladní údaje
Originální název
The effects of wedelolactone on cancer cells depend on its redox state
Autoři
Vydání
19th euroconference on apoptosis, Stocholm, Sweden, 14-17.9, 2011, 2011
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
Genetika a molekulární biologie
Stát vydavatele
Švédsko
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14310/11:00049466
Organizační jednotka
Přírodovědecká fakulta
Klíčová slova anglicky
wedelolactone; topoisomerase IIa; breast cancer
Změněno: 21. 11. 2011 07:37, prof. RNDr. Jan Šmarda, CSc.
Anotace
V originále
The aim of this study was to further characterize the mechanism how wedelolactone affects topoisomerase IIa and cancer cells. Using electrophoretic mobility shift assay we found that wedelolactone inhibited binding of topoisomerase IIa to supercoiled plasmid DNA. The inhibitory effect of wedelolactone on the topoisomerase IIa was reversed by excess of enzyme but not DNA suggesting that wedelolactone exerted its inhibitory effect by interaction with the topoisomerase II protein. The in vitro inhibitory effect of wedelolactone on the topoisomerase IIa activity was redox-dependent as it diminished in the presence of reducing agents, such as DTT, glutathione, N-acetylcysteine and L-ascorbic acid. Similarly, cytotoxicity of wedelolactone in breast cancer MDA-MB-231 cells was inhibited by N-acetylcysteine but enhanced by buthionine sulfoximine, an inhibitor of glutathione synthesis. Finally, we found that wedelolactone can be oxidized in the presence of copper ions to semiquinone/quinone radicals.
Návaznosti
| GA301/09/1115, projekt VaV |
| ||
| GD204/08/H054, projekt VaV |
| ||
| IAA501630801, projekt VaV |
| ||
| MSM0021622415, záměr |
|